Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer Read more about Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia Read more about Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody Read more about A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody
Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX) Read more about Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)
Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML) Read more about Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)
Study of SGR-1505 in Mature B-Cell Neoplasms Read more about Study of SGR-1505 in Mature B-Cell Neoplasms
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers Read more about Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer Read more about Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma Read more about Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors Read more about P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors